Note 4 - Stock-based Compensation

On June 20, 2019, our Board of Directors granted stock options for the purchase of 909,230 shares of our common stock to employees. The stock options awarded contained either service or performance vesting conditions, as described below, have a contractual term of five years and an exercise price equal to the closing price of our common stock on the OTCQB on the date of grant of $2.40. We did not grant any stock options to employees or non-employees during the six months ended June 30, 2018.

Stock options representing the purchase of 456,000 shares of common stock (of the 909,230 stock options granted on June 20, 2019) contained service vesting conditions. The service condition related solely to employees rendering service over a three-year period. These awards vest one-third on the first anniversary of the grant date, and then vest ratably over the remaining twenty-four months, 1/36^th the original award each month.

Stock options representing the purchase of the purchase of 453,230 shares of common stock (of the 909,230 stock options granted on June 20, 2019) vest upon meeting the following performance criteria: (i) 90,646 shares vest when we in-license one new or additional drug; (ii) 90,646 shares vest when our current Phase 2a clinical trial for PCS-499 is complete; and (iii) 271,938 shares vest when we up-list from the OTCQB to either the Nasdaq or NYSE markets. As of June 30, 2019, we are only recognizing compensation cost for the awards related to completion of our current clinical trial. The clinical trial is progressing as planned with no significant adverse events, is nearly fully enrolled, and fully funded. Management does not foresee any reasons why this study will not be completed as planned and believes it is probable that this performance condition will be met in mid-2020. As for the other two awards containing performance conditions, management has determined that until we complete the performance related condition, it is not probable to conclude the performance condition will be achieved. As such, no stock-based compensation expense is being recorded for those two awards.

At June 30, 2019, we had outstanding options to purchase 1,293,630 shares of our common stock of which options for the purchase of 9,000 shares of our common stock were vested. We recorded $66,476 and $125,035 of stock-based compensation expense for the three and six months ended June 30, 2019, respectively. The allocation of stock-based compensation expense between research and development and general and administrative expense was as follows:

No expense was recorded during the three and six months ended June 30, 2018 since we had no stock options outstanding at June 30, 2018.